Eurofins Scientific has announced the acquisition of Beacon Discovery, a drug discovery and contract research organization (CRO) focused on G-Protein Coupled Receptor (GPCR) research. Beacon Discovery joins Eurofins Discovery, a CRO with a portfolio of validated in vitro pharmacology, ADMET, and chemistry services for integrated drug discovery solutions.
Beacon Discovery augments Eurofins Discovery’s capabilities and methods to support drug discovery research and development and the growing R&D outsourcing market.
“Beacon Discovery is very excited to join Eurofins. Joining the Eurofins Discovery organisation expands our opportunity to continue our drug discovery efforts and provide integrated drug discovery services with the additive and complementary capabilities provided by Eurofins Discovery,” Dr. Sunny Al-Shamma, Beacon Discovery’s CEO said.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“Beacon Discovery adds the expertise in GPCR targets and drug discovery and development experience that will advance our offering in integrated drug discovery services for our clients. This transaction is another demonstration of Eurofins’ commitment to provide the most comprehensive portfolio of laboratory services in the discovery pharmacology field which enjoys a strong outsourcing growth trend,” Dr. Gilles Martin, Eurofins’ CEO said.